TheraRadar
Clinical-Stage Companies / Taisho Pharmaceutical

Taisho Pharmaceutical

Pre-Approval PRO BETA

Also known as: Taisho Pharmaceutical Co., Ltd., Taisho Pharmaceutical R&D Inc.

47
Total Trials
9
Phase 3
8
Phase 2
3
Recruiting
319
Score

Pipeline by Phase

Phase 3
9
Phase 2
8
Phase 1
30

Therapeutic Focus

Hyperphosphatemia Patients on Hemodialysis Healthy Volunteers Healthy Subjects Healthy Male Subjects Healthy Volunteer

Clinical Trials (47)

NCT07285291 Phase 3 RECRUITING

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Started: 1/9/2026

NCT07285304 Phase 3 RECRUITING

A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Started: 12/1/2025

NCT06745531 Phase 3 COMPLETED

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Started: 1/6/2025

NCT05461352 Phase 3 COMPLETED

Long-Term Study of TS-142 in Patients with Insomnia

Started: 10/11/2022

NCT05453136 Phase 3 COMPLETED

Phase III Study of TS-142 in Patients with Insomnia

Started: 8/30/2022

NCT04077567 Phase 3 COMPLETED

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Started: 10/1/2019

NCT03434197 Phase 3 COMPLETED

Safety and Efficacy of SFPP in Knee Osteoarthritis

Started: 2/5/2018

NCT07548840 Phase 3 NOT YET RECRUITING

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Started: 4/1/2026

NCT07548853 Phase 3 NOT YET RECRUITING

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

Started: 4/1/2026

NCT06745518 Phase 2 COMPLETED

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Started: 1/6/2025

NCT05699239 Phase 2 COMPLETED

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Started: 2/8/2023

NCT04469023 Phase 2 COMPLETED

Late Phase II Study of TS-142 in Patients with Insomnia

Started: 9/9/2020

NCT03267303 Phase 2 COMPLETED

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy

Started: 10/31/2017

NCT04087707 Phase 2 COMPLETED

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

Started: 9/17/2019

NCT04573725 Phase 2 COMPLETED

Early Phase 2 Clinical Study of TS-142 in Patients with Insomnia Disorder

Started: 7/7/2017

NCT03093025 Phase 2 TERMINATED

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Started: 7/3/2017

NCT00914186 Phase 2 COMPLETED

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

Started: 6/1/2009

NCT07231029 Phase 1 RECRUITING

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Started: 12/23/2025

NCT07084961 Phase 1 COMPLETED

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

Started: 8/5/2025

NCT06837155 Phase 1 COMPLETED

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Started: 3/3/2025

NCT06849778 Phase 1 COMPLETED

An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

Started: 3/22/2025

NCT06837142 Phase 1 COMPLETED

A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

Started: 3/11/2025

NCT04169893 Phase 1 COMPLETED

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

Started: 10/17/2015

NCT05819710 Phase 1 COMPLETED

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Started: 5/15/2023

NCT04557163 Phase 1 COMPLETED

Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)

Started: 10/13/2020

NCT04746105 Phase 1 COMPLETED

A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.

Started: 2/24/2021

NCT03581071 Phase 1 COMPLETED

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

Started: 10/6/2016

NCT04169906 Phase 1 COMPLETED

A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)

Started: 7/6/2016

NCT04873323 Phase 1 COMPLETED

A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

Started: 6/7/2021

NCT04979572 Phase 1 COMPLETED

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Started: 8/16/2021

NCT05624944 Phase 1 COMPLETED

A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment

Started: 12/26/2022

NCT05707897 Phase 1 COMPLETED

A Food Effect Study of TS-142 in Healthy Subjects

Started: 2/15/2023

NCT03591133 Phase 1 COMPLETED

Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)

Started: 12/24/2015

NCT04696952 Phase 1 COMPLETED

A Study to Evaluate Next Day Effects of TS-142 on Driving Performance in Healthy Subjects

Started: 1/16/2021

NCT04631276 Phase 1 COMPLETED

Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects

Started: 12/11/2014

NCT04814771 Phase 1 COMPLETED

Mass Balance Study of TS-142 in Healthy Adult Subjects.

Started: 4/19/2021

NCT03595202 Phase 1 COMPLETED

Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)

Started: 4/3/2017

NCT06596356 Phase 1 COMPLETED

A Mass Balance Study of TS-172 in Healthy Adult Subjects

Started: 9/26/2024

NCT00772512 Phase 1 COMPLETED

A Study Of The Effect Of PF-04802540 On Sleep Measures

Started: 11/1/2008

NCT00756743 Phase 1 COMPLETED

Multiple Dose Safety Study of PF-04802540 in Healthy Volunteers

Started: 9/1/2008

NCT00876304 Phase 1 COMPLETED

Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

Started: 4/1/2009

NCT04464239 Phase 1 COMPLETED

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

Started: 9/14/2020

NCT03919409 Phase 1 COMPLETED

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Started: 6/3/2019

NCT03746067 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Started: 8/21/2015

NCT03742791 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

Started: 6/28/2016

NCT03141658 Phase 1 COMPLETED

Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects

Started: 6/28/2017

NCT02448212 Phase 1 COMPLETED

Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects

Started: 5/1/2015

Drug Candidates

TS-172 20~60 mg/day Placebo TS-172 TS-172 20 mg TS-172 90 mg Moxifloxacin Triazolam and TS-172 TS-172 and itraconazole Placebo (fasting) Placebo (feeding)
Activity Status: Active
Last Trial Started: 4/1/2026
Last Trial Ended: 10/20/2025
Trials (12 months): 6
Completed Trials: 41
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.